Wang Kai, Sun Shijie, Guo Deyu, Zhou Xinyuan, Xiang Yunzhi, Pang Zhaofei, Du Jiajun
Institute of Oncology, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, People's Republic of China.
Department of Healthcare Respiratory Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, People's Republic of China.
Med Oncol. 2025 Jul 14;42(8):330. doi: 10.1007/s12032-025-02887-y.
Normal type II alveolar epithelial cells transform into lung adenocarcinoma through intermediate stages of adenocarcinoma in situ and minimally invasive adenocarcinoma, eventually becoming invasive adenocarcinoma. Transcription factors (TFs) are pivotal in tumorigenesis and development, etc. In this study, we modeled the malignant transformation of AT2 cells into lung adenocarcinoma using single-cell profiling, focusing on TF-mediated transcriptional repression or activation as a key mechanism. We analyzed data from 29 motifs database, including Jaspar, Bergman, Transfac and cisBP, compiling a collection of 18,422 motifs. By integrating Motif analysis to deduce the target genes regulated by transcription factors exhibiting activity alterations across various progression stages of lung adenocarcinoma, and subsequently determining the intersection between these target genes and the differentially expressed genes at each stage, we can pinpoint the target genes that are both differentially expressed and under the regulation of key transcription factors at each stage. Consequently, the regulatory mechanism of TFs on target genes in lung adenocarcinoma was speculated. Furthermore, the transcriptional regulatory network reveals that TFs modulate signaling pathways, cellular metabolism, and biological processes during the transformation process. In addition, leveraging six transcription factors (REBF2, CEBPB, TFCP2, IRF6, ETV4, and BHLHE40) that exhibit progressively increasing activity during the progression of lung adenocarcinoma, we developed a pivotal progression model score, termed the "Lung Adenocarcinoma Transformation TFs Upregulation" (LUAD-TTFs-UP) score, to predict both the progression and prognosis of this disease.
正常的II型肺泡上皮细胞通过原位腺癌和微浸润腺癌的中间阶段转化为肺腺癌,最终发展为浸润性腺癌。转录因子(TFs)在肿瘤发生和发展等过程中起关键作用。在本研究中,我们利用单细胞分析方法模拟了AT2细胞向肺腺癌的恶性转化过程,重点关注TF介导的转录抑制或激活这一关键机制。我们分析了来自29个基序数据库的数据,包括Jaspar、Bergman、Transfac和顺式BP,汇编了一个包含18422个基序的集合。通过整合基序分析来推断在肺腺癌各个进展阶段表现出活性变化的转录因子所调控的靶基因,随后确定这些靶基因与每个阶段差异表达基因的交集,我们能够找出在每个阶段既差异表达又受关键转录因子调控的靶基因。因此,推测了TFs对肺腺癌靶基因的调控机制。此外,转录调控网络揭示了TFs在转化过程中调节信号通路、细胞代谢和生物学过程。另外,利用在肺腺癌进展过程中活性逐渐增加的六个转录因子(REBF2、CEBPB、TFCP2、IRF6、ETV4和BHLHE40),我们开发了一个关键的进展模型评分,称为“肺腺癌转化TFs上调”(LUAD-TTFs-UP)评分,以预测该疾病的进展和预后。